ATE135045T1 - Sekretorische leader-sequenzen - Google Patents

Sekretorische leader-sequenzen

Info

Publication number
ATE135045T1
ATE135045T1 AT89909015T AT89909015T ATE135045T1 AT E135045 T1 ATE135045 T1 AT E135045T1 AT 89909015 T AT89909015 T AT 89909015T AT 89909015 T AT89909015 T AT 89909015T AT E135045 T1 ATE135045 T1 AT E135045T1
Authority
AT
Austria
Prior art keywords
leu
ser
phe
ile
lys
Prior art date
Application number
AT89909015T
Other languages
English (en)
Inventor
Andrew Robert Goodey
Graham Paul Belfield
Darrell Sleep
Original Assignee
Delta Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB888817598A external-priority patent/GB8817598D0/en
Priority claimed from GB898906920A external-priority patent/GB8906920D0/en
Application filed by Delta Biotechnology Ltd filed Critical Delta Biotechnology Ltd
Application granted granted Critical
Publication of ATE135045T1 publication Critical patent/ATE135045T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Surface Acoustic Wave Elements And Circuit Networks Thereof (AREA)
AT89909015T 1988-07-23 1989-07-14 Sekretorische leader-sequenzen ATE135045T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB888817598A GB8817598D0 (en) 1988-07-23 1988-07-23 Dna & peptide sequences
GB898906920A GB8906920D0 (en) 1989-03-28 1989-03-28 Peptide and dna sequences

Publications (1)

Publication Number Publication Date
ATE135045T1 true ATE135045T1 (de) 1996-03-15

Family

ID=26294196

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89909015T ATE135045T1 (de) 1988-07-23 1989-07-14 Sekretorische leader-sequenzen

Country Status (15)

Country Link
US (1) US5302697A (de)
EP (1) EP0387319B1 (de)
JP (1) JP3092811B2 (de)
KR (1) KR100195632B1 (de)
AT (1) ATE135045T1 (de)
AU (1) AU633020B2 (de)
CA (1) CA1340547C (de)
DE (1) DE68925893T2 (de)
DK (1) DK175853B1 (de)
FI (1) FI104564B (de)
GB (1) GB2230268B (de)
HU (1) HU213571B (de)
IE (1) IE62266B1 (de)
IL (1) IL91024A (de)
WO (1) WO1990001063A1 (de)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340772C (en) 1987-12-30 1999-09-28 Patricia Tekamp-Olson Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences
US5759802A (en) * 1988-10-26 1998-06-02 Tonen Corporation Production of human serum alubumin A
DK105489D0 (da) * 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid
US5766883A (en) * 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
FR2650598B1 (fr) * 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
DK300090D0 (da) * 1990-12-19 1990-12-19 Novo Nordisk As Fremgangsmaade til fremstilling af leadersekvenser
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5521086A (en) * 1993-09-16 1996-05-28 Cephalon, Inc. Secretion sequence for the production of a heterologous protein in yeast
DE69636536T2 (de) * 1995-02-03 2007-10-25 Asahi Glass Co., Ltd. Sekretionssignal-Gen und dieses enthaltender Expressionsvektor
US5712114A (en) * 1995-06-06 1998-01-27 Basf Aktiengesellschaft Compositions for expression of proteins in host cells using a preprocollagen signal sequence
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
GB9712370D0 (en) 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems
ATE406577T1 (de) * 1997-11-07 2008-09-15 Conjuchem Biotechnologies Inc Methoden zum screening von affinitätsmarker- bibliotheken
GB9902000D0 (en) 1999-01-30 1999-03-17 Delta Biotechnology Ltd Process
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
US20060084794A1 (en) * 2001-04-12 2006-04-20 Human Genome Sciences, Inc. Albumin fusion proteins
US20050244931A1 (en) * 2001-04-12 2005-11-03 Human Genome Sciences, Inc. Albumin fusion proteins
US20050054051A1 (en) * 2001-04-12 2005-03-10 Human Genome Sciences, Inc. Albumin fusion proteins
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
WO2003030821A2 (en) * 2001-10-05 2003-04-17 Human Genome Sciences, Inc. Albumin fusion proteins
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
WO2003059934A2 (en) * 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
US20060122374A1 (en) 2002-02-07 2006-06-08 Peter Mertins Albumin-fused anti-angiogenesis peptides
GB0217033D0 (en) 2002-07-23 2002-08-28 Delta Biotechnology Ltd Gene and polypeptide sequences
WO2005055944A2 (en) 2003-12-05 2005-06-23 Cincinnati Children's Hospital Medical Center Oligosaccharide compositions and use thereof in the treatment of infection
GB0329722D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Modified plasmid and use thereof
GB0329681D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Gene expression technique
US9057061B2 (en) 2003-12-23 2015-06-16 Novozymes Biopharma Dk A/S Gene expression technique
CA2552590A1 (en) 2004-01-05 2005-07-21 Emd Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
EP2330200B1 (de) 2004-12-23 2017-04-05 Albumedix A/S Genexpressionstechnik
EP1816201A1 (de) 2006-02-06 2007-08-08 CSL Behring GmbH Modifizierter Koagulationsfaktor VIIa mit verbesserter 'half-life'-Stabiltät
DK2046826T3 (da) 2006-07-24 2011-10-24 Biorexis Pharmaceutical Corp Exendin-fusionsproteiner
WO2008019368A2 (en) 2006-08-07 2008-02-14 Teva Biopharmaceuticals Usa, Inc. Albumin-insulin fusion proteins
WO2008051383A2 (en) * 2006-10-19 2008-05-02 Amgen Inc. Use of alcohol co-solvents to improve pegylation reaction yields
PE20081140A1 (es) * 2006-10-25 2008-09-22 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
MX2009012609A (es) 2007-05-22 2009-12-07 Amgen Inc Composiciones y metodos para producir proteinas de fusion bioactivas.
EP2594583A1 (de) 2007-08-08 2013-05-22 Novozymes Biopharma DK A/S Transferrinvarianten und Konjugate
US20110294988A1 (en) 2009-02-06 2011-12-01 Novozymes Bio Pharma DK A/S Purification Process
SG172789A1 (en) 2009-02-11 2011-08-29 Novozymes Biopharma Dk As Albumin variants and conjugates
JP2012521197A (ja) 2009-03-20 2012-09-13 アムジエン・インコーポレーテツド 担体免疫グロブリンおよびその使用
AU2010321832B2 (en) 2009-11-20 2014-08-14 Amgen Inc. Anti-Orai1 antigen binding proteins and uses thereof
US20140072983A1 (en) 2010-08-10 2014-03-13 Amgen Inc. Dual function in vitro target binding assay for the detection of neutralizing antibodies against target antibodies
CA2885176C (en) 2010-09-22 2018-10-23 Amgen Inc. Carrier immunoglobulins and uses thereof
WO2012099983A1 (en) 2011-01-18 2012-07-26 Amgen Inc. Nav1.7 knockout mice and uses thereof
AU2012222833B2 (en) 2011-03-03 2017-03-16 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
PH12013501865A1 (en) 2011-03-16 2014-01-06 Amgen Inc Potent and selective inhibitors of nav1.3 and nav1.7
US20150201588A1 (en) 2012-02-22 2015-07-23 Amgen Inc. Autologous Mammalian Models Derived from Induced Pluripotent Stem Cells and Related Methods
IN2015DN01115A (de) 2012-07-13 2015-06-26 Zymeworks Inc
WO2014165277A2 (en) 2013-03-12 2014-10-09 Amgen Inc. POTENT AND SELECTIVE INHIBITORS OF Nav1.7
US10239951B2 (en) 2013-05-08 2019-03-26 Zymeworks Inc. Bispecific HER2 and HER3 antigen binding constructs
US11078464B2 (en) 2013-08-30 2021-08-03 Amgen Inc. High titer recombinant AAV vector production in adherent and suspension cells
US10463716B2 (en) 2014-10-13 2019-11-05 University Of Maryland, Baltimore Methods for treating cardiovascular dysfunction and improving fluid homeostasis with Elabela peptide hormone
EP3207146B1 (de) 2014-10-15 2021-09-29 Amgen Inc. Promotor und regulatorische elemente zur verbesserten expression von heterologen genen in wirtszellen
CA2874083C (en) 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
WO2017112847A1 (en) 2015-12-22 2017-06-29 Albumedix A/S Improved protein expression strains
JP7146637B2 (ja) 2015-12-22 2022-10-04 アルブミディクス リミティド 改善されたタンパク質発現株
ES2823173T3 (es) 2016-01-27 2021-05-06 Just Biotherapeutics Inc Promotor híbrido y usos del mismo
CN109937034B (zh) 2016-11-21 2022-09-16 济世-伊沃泰克生物制品有限公司 阿柏西普制剂及其用途
EP4026908A1 (de) 2017-06-20 2022-07-13 Albumedix Ltd Verbesserte proteinexpressionsstämme
MY199833A (en) 2017-08-17 2023-11-24 Just Evotec Biologics Inc Method of purifying glycosylated protein from host cell galectins and other contaminants
MY202872A (en) 2017-11-20 2024-05-28 Just Evotec Biologics Inc Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
JP2022520793A (ja) 2019-02-15 2022-04-01 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド 自動バイオ製造システム、施設、及びプロセス
US12629445B2 (en) 2020-03-20 2026-05-19 Bard Peripheral Vascular, Inc. Reactive hydrogel forming formulations and related methods, including methods of preparation
US12161777B2 (en) 2020-07-02 2024-12-10 Davol Inc. Flowable hemostatic suspension
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent
WO2022146917A1 (en) 2020-12-28 2022-07-07 Davol Inc. Reactive dry powdered hemostatic materials comprising a protein and a multifunctionalized modified polyethylene glycol based crosslinking agent
EP4370647A1 (de) 2021-07-15 2024-05-22 Just-Evotec Biologics, Inc. Bidirektionales perfusionssystem mit tangentialer strömungsfiltration (tff)
JP2025506122A (ja) 2022-02-10 2025-03-07 アムジエン・インコーポレーテツド ハイスループット配列決定のための抗体タンパク質産物発現コンストラクト
CA3266599A1 (en) 2022-09-07 2024-11-07 Quantitative Biosciences, Inc. UNIQUE VARIABLE DOMAIN ANTIBODIES SPECIFIC TO FENTANYL AND USE IN A CONTINUOUS AGGLUTINATION TEST
EP4702164A1 (de) 2023-04-24 2026-03-04 Quantitative Biosciences, Inc. Manipulierte biosensorstämme von e. coli zur kontinuierlichen aeroben detektion von analyten
CN122349567A (zh) 2023-12-11 2026-07-07 济世易为生物有限公司 利用反式剪接和拆分型选择标记的蛋白质表达
EP4711442A1 (de) 2024-09-15 2026-03-18 Quantitative Biosciences, Inc. Mikrofluidischer chip zur parallelen kultivierung mikrobieller biosensorstämme

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207926A (en) * 1983-04-25 1988-04-29 Genentech Inc Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast
NZ207925A (en) * 1983-04-25 1988-05-30 Genentech Inc Yeast expression vehicle consisting of a yeast promoter and signal peptide encoding region linked to a heterologus peptide coding region; expression and culture
US4588684A (en) * 1983-04-26 1986-05-13 Chiron Corporation a-Factor and its processing signals
FR2593518B1 (fr) * 1985-05-02 1989-09-08 Transgene Sa Vecteurs d'expression et de secretion de l'hirudine par les levures transformees
AU5912586A (en) * 1985-06-20 1986-12-24 Salk Institute Biotechnology/Industrial Associates, Inc., The Alpha-factor leader peptide-facilitated secretion from transformed s cerevisiae
RU2091490C1 (ru) * 1985-10-25 1997-09-27 Зимодженетикс, Инк. Способ получения гетерологичного полипептида в эукариотических микроорганизмов
JP2523562B2 (ja) * 1985-10-25 1996-08-14 ザイモジェネティックス インコーポレーテッド 外来タンパク質を分泌することを目的としたｂａｒ１の使用法
GB8613388D0 (en) * 1986-06-03 1986-07-09 Delta Biotechnology Ltd Induction of galactose regulated gene expression in yeast
IT1196484B (it) * 1986-07-11 1988-11-16 Sclavo Spa Vettore ad espressione e secrezione in lieviti,utile per la preparazione di proteine eterologhe
JP2507874B2 (ja) * 1986-11-27 1996-06-19 工業技術院長 分泌シグナルペプチドをコ−ドするｄｎａ配列

Also Published As

Publication number Publication date
GB2230268A (en) 1990-10-17
HU894572D0 (en) 1991-05-28
IL91024A (en) 1995-08-31
IE62266B1 (en) 1995-01-11
AU633020B2 (en) 1993-01-21
EP0387319B1 (de) 1996-03-06
DK72990D0 (da) 1990-03-21
KR100195632B1 (ko) 1999-06-15
DE68925893D1 (de) 1996-04-11
GB8928849D0 (en) 1990-07-18
FI104564B (fi) 2000-02-29
US5302697A (en) 1994-04-12
EP0387319A1 (de) 1990-09-19
DE68925893T2 (de) 1996-08-08
FI901428A0 (fi) 1990-03-21
CA1340547C (en) 1999-05-18
HUT57829A (en) 1991-12-30
AU4042789A (en) 1990-02-19
HU213571B (en) 1997-08-28
DK72990A (da) 1990-03-21
IL91024A0 (en) 1990-02-09
IE892361L (en) 1990-01-23
JPH03500370A (ja) 1991-01-31
KR920700288A (ko) 1992-02-19
JP3092811B2 (ja) 2000-09-25
WO1990001063A1 (en) 1990-02-08
DK175853B1 (da) 2005-04-04
GB2230268B (en) 1992-01-29

Similar Documents

Publication Publication Date Title
DK175853B1 (da) Sekretoriske ledersekvenser
IL87255A0 (en) Dna constructs containing a kluyveromyces alphafactor leader sequence for directing secretion of heterologous polypeptides
EP0218191A3 (de) Herstellung von Mehrschichtstrukturen durch dielektrische Heizung eines Klebefilms
NO180593C (no) Fremgangsmåte for fremstilling, i Saccharomyces cerevisiae, av et heterologt protein i homogen form
UA27706C2 (uk) Спосіб одержання гетерологічного поліпептиду
DK0870039T3 (da) Rekombinante fusionsproteiner til væksthormon og serumalbumin
CA2403842A1 (en) Increased production of secreted proteins by recombinant eukaryotic cells
DK0746611T3 (da) Fremgangsmåde til forøgelse af produktion af disulfid-bundne rekombinante proteiner af Saccharomyces Cerevisiae
EP1247865A3 (de) Antikörper und ihre therapeutische Verwendung
DK0782625T3 (da) Ekspression af og eksportteknologi for proteiner som immunfusiner
EP0361991A3 (de) Verfahren zur mikrobiologischen Herstellung von menschlichem Serumalbumin und anderen heterologen Proteinen in Hefe
EP0063949A3 (en) Plasmids coding for b. thuringiensis crystal protein, their production and their use in creating genetically engineered bacterial strains, the aforesaid strains per se and their use in producing said protein, said protein so-produced, insecticidal formulations comprising the same and a method of producing an insecticidal effect
CA2060666A1 (en) Antigenic epitopes present on membrane-bound but not secreted iga
IT8621106A1 (it) Vettore ad espressione e secrezione in lieviti, utile per la preparazione di proteine eterologhe
ATA192895A (de) Herstellung von proteinen aus pro-proteinen durch fusionsproteine abgeleitet von furin oder furinanalogen
IE832452L (en) Lymphocyte growth factor
FI885296L (fi) Rekombinant hiv-2 polypeptid.
WO2000050616A3 (en) Sequences for improving the efficiency of secretion of non-secreted proteins from mammalian and insect cells
EP0385659A3 (de) Multifunktionale Polypeptide und Verfahren zu deren Herstellung
EP0352060A3 (de) Expressionsplasmid und dessen Verwendung
ATE100140T1 (de) Herstellung von schimaeren antikoerpern durch homologe rekombination.
ATE91303T1 (de) Verfahren zur herstellung von peptiden durch spezifische spaltung von gentechnisch gewonnenen fusionsproteinen mit collagenasen.
FI934079L (fi) Menetelmä fuusioproteiinin valmistamiseksi

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time